BerGenBio
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including cancer and severe respiratory infections. AXL: a promising target to treat life-threatening diseases The tyrosine kinase target AXL is known to play an important role in both the innate and adaptive immune systems, BerGenBio is developing two highly selective AXL inhibitors bemcentinib and tilvestamab. Business model: R&D excellence and strategic partnerships BerGenBio is leveraging its solid leadership position in understanding the role of AXL and related kinase signalling in diseases of high unmet need to develop a diversified pipeline of selective AXL inhibitors.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-05 16:49 |
Regulatory News Service
BerGenBio ASA - Updated key information related to the rights issue
|
English | 10.0 KB | |
| 2025-08-04 13:40 |
Declaration of Voting Results & Voting Rights Announcements
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
|
Norwegian | 794.1 KB | |
| 2025-08-04 13:40 |
Regulatory News Service
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights is…
|
English | 2.2 KB | |
| 2025-07-03 14:53 |
Regulatory News Service
BerGenBio ASA: Notice of Extraordinary General Meeting - Attachment: BerGenBio_…
|
Norwegian | 441.1 KB | |
| 2025-07-03 14:53 |
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Extraordinary General Meeting
|
English | 2.6 KB | |
| 2025-06-30 22:30 |
Regulatory News Service
BerGenBio ASA - Key information related to the rights issue
|
English | 10.0 KB | |
| 2025-06-30 22:05 |
Net Asset Value
Announcement of fully underwritten rights issue - Attachment: Attachment_overvi…
|
English | 101.2 KB | |
| 2025-06-30 22:05 |
Regulatory News Service
Announcement of fully underwritten rights issue
|
English | 21.0 KB | |
| 2025-06-30 22:00 |
Regulatory News Service
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer ther…
|
English | 19.5 KB | |
| 2025-06-26 11:29 |
Declaration of Voting Results & Voting Rights Announcements
BerGenBio ASA - Minutes from the annual general meeting 2025 - Attachment: BerG…
|
Norwegian | 419.9 KB | |
| 2025-06-26 11:29 |
Declaration of Voting Results & Voting Rights Announcements
BerGenBio ASA - Minutes from the annual general meeting 2025
|
English | 1.1 KB | |
| 2025-06-03 19:22 |
Regulatory News Service
BerGenBio ASA: Update on Strategic Review Process and Status of Activities
|
English | 2.6 KB | |
| 2025-06-03 15:55 |
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Annual General Meeting - Attachment: Notice_of_AGM_Ber…
|
Norwegian | 424.8 KB | |
| 2025-06-03 15:55 |
Pre-Annual General Meeting Information
BerGenBio ASA: Notice of Annual General Meeting
|
English | 2.6 KB | |
| 2025-04-30 07:51 |
Pre-Annual General Meeting Information
Financial calendar
|
English | 666 bytes |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |